Barclays’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-798
Closed -$40K 4410
2021
Q3
$40K Buy
+798
New +$41.6K ﹤0.01% 4156

Other funds holding IDNA

Barclays's IDNA Position: Q4 2021 in Review

Barclays sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q4 2021, closing a stake of 798 shares — an estimated $40K sold.

Barclays first reported a position in IDNA in Q3 2021 and held it in 1 quarter. The position peaked at $40K in Q3 2021. 103 funds tracked by Wall St. Rank hold IDNA as of Q4 2021.

  • Barclays reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 798 iShares Genomics Immunology and Healthcare ETF shares in Q4 2021, an estimated $40K.
  • Barclays first reported a position in iShares Genomics Immunology and Healthcare ETF in Q3 2021 and held it in 1 quarter.
  • Barclays's iShares Genomics Immunology and Healthcare ETF position peaked at $40K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.